Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran

International Clinical Psychopharmacology

Volumn 21, Issue 3, 2006, Pages 153-158

  Puozzo, Christian ^a   Hermann, Philippe ^a   Chassard, Didier ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Aster Cephac   (France)

Author keywords

Co administration; Fluoxetine; Milnacipran; Pharmacokinetics; Tolerance

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG METABOLITE; F 2800; FLUOXETINE; MILNACIPRAN; NORFLUOXETINE; NORMILNACIPRAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONIN SYNDROME; STEADY STATE; VOLUNTEER; VOMITING;

ADULT; AREA UNDER CURVE; CYCLOPROPANES; CYTOCHROME P-450 CYP2D6; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHODS; NAUSEA; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; VOMITING;

EID: 33646705158     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000188217.69537.dc     Document Type: Article

References (15)

1. Altamura AC, Moro AR, Percudani M (1994). Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26: 201-214.
2. Benfield P, Heel RC, Lewis SP (1986). Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 481-508.
3. Bergstrom RF, Peyton AL, Lemberger L (1992). Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51: 239-248.
4. Bonnaud B, Cousse H, Mouzin G, Briley M, Stenger A, Fauran F, Couzinier JP (1987). 1-Aryl-2- (aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants. J Med Chem 30: 318-325.
5. Caccia S (1998). Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302.
6. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K (1996). Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78.
7. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996). Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4): 41-46.
8. Montgomery SA, Prost JF, Solles A, Briley M (1996). Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 11 (Suppl 4): 47-51.
9. Puozzo C, Albin H, Vincon G, Deprez D, Raymond JM, Amouretti M (1998). Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 23: 273-279.
10. Puozzo C, Leonard BE (1996). Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27.
11. Puozzo C, Panconi E, Deprez D (2002). Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 17 (Suppl 1): S25-S35.
12. Puozzo C, Lens S, Reh C, Michaelis K, Rosillon D, Deroubaix X, Deprez D (2005). Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in antidepressant metabolism. Clin Pharmacokinet 44:977-978.
13. Sawada Y, Ohtani H (2001). Pharmacokinetics and drug interactions of antidepressive agents. Nippon Rinsho 59:1539-1545.
14. Steinijans VW, Hartmann M, Huber R, Radtke HW (1996). Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther 34 (Suppl 1):S25-S30.
15. Vandel S, Bertschy G, Bouquet S, Bonin B, Vittouris N (1994). Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man. Therapie 49:141-142.